SecBot SecBot

ORKA drug pipeline

Oruka Therapeutics, Inc. · 3 rated drugs
$105.35
+0.3% 1-day · Nov 13
Next catalyst
None dated
No dated FDA catalyst on file
Typical move on FDA news
No history
No past FDA events with prices
IV rank
No data
No current options data
Rated drugs
3
1 bullish · 2 neutral
Phase 3 trials
0
0 with results posted

Drugs

soonest catalyst first
▲ bullish
Impact
PhasePhase 2b
Time to marketIf Phase 3 trials begin in 1H 2027 and run successfully, a BLA submission and potential FDA approval would likely be several years away, possibly in the 2029-2030 timeframe. The company has stated its $1.1 billion cash position funds operations through a BLA filing.

ORKA-001 Updated Nov 9

What to watch

The key catalyst to watch is the EVERLAST-A 52-week data expected in December 2026, which will demonstrate whether ORKA-001's skin-clearing responses hold up a full year after just two doses. Strong durability would reinforce the ultra-durable dosing thesis and support the Phase 3 design. Weak durability would challenge the core value proposition. Phase 3 initiation in 1H 2027 and ORKA-002 Phase 2 data in Q1 2027 are secondary catalysts. The $1.1B cash runway removes financing overhang through a BLA filing.

Bull case
  • Highly consistent efficacy across two independent Phase 2 trials: 61-63% complete skin clearance (PASI 100) at Week 16, with responses deepening to 71% at Week 28 without additional dosing
  • Ultra-long dosing interval potential (1-2 injections per year) could be a significant competitive advantage over current IL-23 inhibitors that require dosing every 8-12 weeks
  • $1.1 billion cash position funds operations through BLA filing, eliminating near-term dilution risk
Bear case
  • Still a clinical-stage company with no approved products; regulatory and commercial risks remain significant
  • Cross-trial comparisons to approved IL-23 inhibitors (Skyrizi, Tremfya) are not head-to-head; Phase 3 data may show different relative efficacy versus these entrenched multi-billion-dollar brands
  • Stock has already rallied substantially (52-week range $25-$115, up roughly 4x from lows), potentially pricing in success before Phase 3 data
● neutral
Impact
PhasePhase 2
Time to marketIf Phase 2 data are positive, Phase 3 trials would likely follow, with a potential BLA filing and launch estimated around 2031-2033 per analyst estimates.

ORKA-002 Updated Nov 9

What to watch

The next hard catalyst for ORKA-002 is the 16-week topline data from the ORCA-SURGE Phase 2 trial in moderate-to-severe plaque psoriasis, expected in 1Q 2027. Positive efficacy and safety data would validate the IL-17A/F platform and support advancement toward Phase 3, while disappointing results could pressure the stock given the high expectations baked into the current valuation.

Bull case
  • Phase 1 interim data showed a half-life of 75-80 days, supporting potential for twice-per-year dosing in psoriasis and quarterly dosing in hidradenitis suppurativa, a significant convenience advantage over current standard-of-care IL-17 inhibitors that require monthly or every-2-month injections.
  • The company's platform is validated by ORKA-001's strong Phase 2b data (61% PASI 100 complete skin clearance at Week 16), and Oruka has a $1.1B cash position that funds operations through a planned BLA filing.
  • Analyst consensus is overwhelmingly bullish: 10 Buy, 1 Hold, 0 Sell ratings, with a mean price target of $156 (51.8% upside from the $102.86 close).
Bear case
  • No efficacy data for ORKA-002 have been reported yet; only Phase 1 pharmacokinetic and safety data are available, so the drug's ability to match or beat marketed IL-17 inhibitors is unproven.
  • The stock has already rallied roughly 700% from its 52-week low of $25.23, and a Seeking Alpha analysis argues the current valuation far exceeds risk-adjusted fundamentals, with ORKA-002 not expected to launch until 2031-2033.
  • The IL-17A/F market is crowded with approved drugs including Cosentyx (Novartis), Taltz (Eli Lilly), Bimzelx (UCB), and Sotyktu (BMS), all of which will have years of market presence and real-world data before ORKA-002 could launch.
● neutral
Impact
PhasePreclinical / entering Phase 1
Time to marketORKA-004 has not yet entered clinical trials. Assuming Phase 1 starts in late 2026 or early 2027, a potential approval would likely be 5-8 years away, if clinical development is successful.

ORKA-004 Updated Nov 9

What to watch

Watch for an announcement that ORKA-004 has entered clinical development (expected Q4 2026 per prior guidance). The more impactful near-term catalysts for ORKA stock are the 52-week EVERLAST-A data for ORKA-001 due December 2026 and ORKA-002 Phase 2 data due Q1 2027. ORKA-004 is a pipeline-extender, not a near-term value driver.

Bull case
  • ORKA-004 targets TL1A, a validated mechanism in inflammatory bowel disease (IBD), a multi-billion-dollar market with high unmet need.
  • The half-life extended format could enable less frequent dosing, a potential competitive advantage over existing anti-TL1A antibodies.
  • Oruka has a $1.2B cash position (as of Q3 2026) to fund development through multiple catalysts, including ORKA-004's entry into the clinic.
Bear case
  • ORKA-004 is a preclinical/early-stage asset with no clinical data yet; it will take years to generate proof-of-concept data.
  • The TL1A space is increasingly competitive: Prometheus Biosciences (acquired by Merck) and others are already in late-stage development with anti-TL1A antibodies for IBD.
  • Oruka's primary focus and value driver is ORKA-001 (psoriasis); ORKA-004 is a smaller pipeline program that receives less attention and resources.